Smith & Nephew SNATS PE Ratio 2006-2019 | SNN

Current and historical p/e ratio for Smith & Nephew SNATS (SNN) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Smith & Nephew SNATS PE ratio as of October 16, 2019 is 0.00.
Smith & Nephew SNATS PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-10-16 47.46 inf
2019-06-30 43.54 0 0.00
2018-12-31 37.38 0 0.00
2018-06-30 37.24 0 0.00
2017-12-31 34.33 0 0.00
2017-06-30 33.94 0 0.00
2016-12-31 28.95 $0.36 80.41
2015-12-31 33.62 $0.59 56.99
2015-06-30 31.85 $0.79 40.31
2014-12-31 34.10 $1.13 30.28
2014-09-30 31.04 $1.13 27.56
2014-06-30 32.91 $1.16 28.28
2014-03-31 27.87 $1.25 22.33
2013-12-31 26.14 $1.23 21.29
2013-09-30 22.56 $1.18 19.05
2013-06-30 20.27 $1.22 16.67
2013-03-31 20.57 $1.59 12.95
2012-12-31 19.74 $1.63 12.10
2012-09-30 19.45 $1.63 11.95
2012-06-30 17.64 $1.63 10.84
2012-03-31 17.64 $1.31 13.44
2011-12-31 16.82 $1.30 12.94
2011-09-30 15.50 $1.40 11.10
2011-06-30 18.78 $1.40 13.46
2011-03-31 19.40 $1.36 14.22
2010-12-31 18.07 $1.38 13.13
2010-09-30 15.51 $1.26 12.35
2010-06-30 16.06 $1.24 12.91
2010-03-31 16.96 $1.20 14.09
2009-12-31 17.37 $1.06 16.32
2009-09-30 15.16 $1.04 14.64
2009-06-30 12.55 $0.91 13.82
2009-03-31 10.40 $0.87 11.93
2008-12-31 10.75 $0.84 12.80
2008-09-30 17.57 $0.80 21.86
2008-06-30 18.12 $0.68 26.81
2008-03-31 21.72 $0.68 31.94
2007-12-31 18.90 $0.68 27.63
2007-09-30 20.08 $0.76 26.28
2007-06-30 20.34 $0.77 26.35
2007-03-31 20.71 $0.76 27.39
2006-12-31 17.07 $1.44 11.82
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $20.446B $4.904B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $144.323B 20.26
Abbott Laboratories (ABT) United States $141.074B 26.52
Stryker (SYK) United States $79.557B 27.51
Boston Scientific (BSX) United States $52.891B 25.66
Baxter (BAX) United States $44.520B 27.00
EssilorLuxottica Societe Anonyme (ESLOY) France $32.321B 0.00
Zimmer Biomet Holdings (ZBH) United States $27.767B 17.77
Coloplast (CLPBY) Denmark $25.229B 40.28
Lonza Group Ag (LZAGY) Switzerland $24.768B 0.00
Terumo (TRUMY) Japan $23.431B 29.24
ResMed (RMD) United States $18.578B 35.40
Sunny Optical Technology (SNPTF) China $16.014B 0.00
Bio-Rad Laboratories (BIO) United States $9.880B 52.96
Insulet (PODD) United States $9.176B 543.75
Perrigo (PRGO) Ireland $7.218B 13.30
Hill-Rom Holdings (HRC) United States $6.641B 19.80
Canopy Growth (CGC) Canada $6.561B 0.00
Haemonetics (HAE) United States $6.400B 48.30
William Demant Holdings (WILYY) Denmark $5.988B 0.00
GN STORE NORD (GNNDY) Denmark $5.322B 27.49
Shandong Weigao Medical Polymer (SHWGF) China $4.296B 0.00
Aurora Cannabis (ACB) Canada $3.611B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.590B 0.00
Neogen (NEOG) United States $3.348B 56.02
NuVasive (NUVA) United States $3.295B 26.27
ICU Medical (ICUI) United States $3.139B 20.36
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.427B 0.00
Quidel (QDEL) United States $2.414B 23.97
Agios Pharmaceuticals (AGIO) United States $1.901B 0.00
National Vision Holdings (EYE) United States $1.871B 40.39
Cardiovascular Systems (CSII) United States $1.582B 0.00
Aphria (APHA) $1.099B 0.00
VAREX IMAGING (VREX) United States $1.093B 25.19
AtriCure (ATRC) United States $0.999B 0.00
Phibro Animal Health (PAHC) United States $0.870B 14.15
Eagle Pharmaceuticals (EGRX) United States $0.830B 21.16
NanoString Technologies (NSTG) United States $0.769B 0.00
PetIQ (PETQ) United States $0.746B 17.62
Omeros (OMER) United States $0.734B 0.00
Lantheus Holdings (LNTH) United States $0.731B 19.21
LeMaitre Vascular (LMAT) United States $0.643B 38.13
Cerus (CERS) United States $0.603B 0.00
Surmodics (SRDX) United States $0.581B 110.51
Quanterix (QTRX) United States $0.554B 0.00
MacroGenics (MGNX) United States $0.550B 0.00
TG Therapeutics (TGTX) United States $0.494B 0.00
OraSure Technologies (OSUR) United States $0.481B 22.27
Meridian Bioscience (VIVO) United States $0.404B 12.60
Owens & Minor (OMI) United States $0.392B 11.74
Zynex (ZYXI) United States $0.374B 39.69
Utah Medical Products (UTMD) United States $0.342B 25.03
BioLife Solutions (BLFS) United States $0.329B 101.19
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.308B 0.00
United Health Products (UEEC) United States $0.240B 0.00
Bovie Medical (APYX) United States $0.230B 0.00
Vapotherm (VAPO) United States $0.175B 0.00
Rockwell Medical (RMTI) United States $0.153B 0.00
Cytosorbents (CTSO) United States $0.143B 0.00
Female Health (VERU) United States $0.135B 0.00
Fonar (FONR) United States $0.127B 8.94
InfuSystems Holdings (INFU) United States $0.126B 0.00
Chembio Diagnostics (CEMI) United States $0.098B 0.00
Chimerix (CMRX) United States $0.095B 0.00
United-Guardian (UG) United States $0.086B 20.43
Nephros (NEPH) United States $0.074B 0.00
MTech Acquisition (KERN) United States $0.060B 0.00
MRI Interventions (MRIC) United States $0.056B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.054B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Surface Oncology (SURF) United States $0.035B 0.00
Senestech (SNES) United States $0.023B 0.00
Trinity Biotech (TRIB) Ireland $0.021B 0.00
GUARDION HEALTH (GHSI) United States $0.019B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Myomo (MYO) United States $0.011B 0.00
Capricor Therapeutics (CAPR) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00